These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

985 related articles for article (PubMed ID: 30336540)

  • 21. Stool DNA testing for early detection of colorectal cancer: systematic review using the HTA Core Model
    Stürzlinger H; Conrads-Frank A; Eisenmann A; Invansits S; Jahn B; Janzic A; Jelenc M; Kostnapfel T; Mencej Bedrac S; Mühlberger N; Siebert U; Sroczynski G;
    Ger Med Sci; 2023; 21():Doc06. PubMed ID: 37426885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates.
    Berger BM; Ahlquist DA
    Pathology; 2012 Feb; 44(2):80-8. PubMed ID: 22198259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
    Lohsiriwat V
    Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening.
    Chen J; Lin J; Zhang L; Chen M; Yu X; Wu Y; Wang T; Xu R; Tian T; Sun A; Zhang T; Lu Y; Ba Z; Cheng X; Chen M
    Clin Lab; 2022 Dec; 68(12):. PubMed ID: 36546736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of combined detection of multigene mutation and SDC2/SFRP2 methylation in stool specimens for colorectal cancer early diagnosis.
    Lin J; Zhang L; Chen M; Chen J; Wu Y; Wang T; Lu Y; Ba Z; Cheng X; Xu R; Tian T; Sun A; Zhang T; Chen M
    Int J Colorectal Dis; 2022 Jun; 37(6):1231-1238. PubMed ID: 35499710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.
    van Lanschot MC; Carvalho B; Coupé VM; van Engeland M; Dekker E; Meijer GA
    BMC Cancer; 2017 Feb; 17(1):116. PubMed ID: 28173852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fecal occult blood test as a tool for improved outpatient qualification for colonoscopy. A single-center experience and 10-year follow-up survey.
    Banaszkiewicz Z; Budzyński J; Tojek K; Jarmocik P; Frasz J; Mrozowski M; Świtoński M; Jawień A
    Adv Med Sci; 2017 Mar; 62(1):171-176. PubMed ID: 28282604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study.
    Wei SC; Tsao PN; Wang YT; Lin BR; Wu DC; Tsai WS; Chen JS; Wong JM
    Cancer Med; 2019 Jul; 8(7):3583-3591. PubMed ID: 31063258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population.
    Sun M; Liu J; Hu H; Guo P; Shan Z; Yang H; Wang J; Xiao W; Zhou X
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2423-2432. PubMed ID: 31456088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.
    Iannone A; Losurdo G; Pricci M; Girardi B; Massaro A; Principi M; Barone M; Ierardi E; Di Leo A
    J Gastrointest Cancer; 2016 Jun; 47(2):143-51. PubMed ID: 26922358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Faecal occult blood testing for colorectal cancer screening: the past or the future.
    Benton SC; Seaman HE; Halloran SP
    Curr Gastroenterol Rep; 2015 Feb; 17(2):428. PubMed ID: 25673567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.